13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001816307
Total reported value
$962.2M
$962.2M
65 檔
17.0%
As reported in its official Q2 2025 Form 13F filing, Silverarc Capital Management, LLC's tracked investment portfolio stood at $962.2M with 65 total positions.
During Q2 2025, Silverarc Capital Management, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ✓ | Merus N V | Stock-Other | 7.20% | — | -8.51% | |
| 2 | AKRO | Akero Therapeutics Inc | Stock-Other | 7.02% | — | -0.86% | |
| 3 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 6.25% | — | -34.36% | |
| 4 | URGN | UroGen Pharma Ltd. | Stock-Other | 5.11% | +2.22% | +46.43% | |
| 5 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 4.67% | +0.87% | +18.71% | |
| 6 | INSM | Insmed Inc | Stock-Healthcare | 4.62% | -0.22% | -22.50% | |
| 7 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 3.82% | -5.91% | EXIT | |
| 8 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 3.78% | — | +124.53% | |
| 9 | ✓ | Merus N V | Stock-Other | 3.71% | — | — | |
| 10 | ETNBGBP | 89bio Inc | Stock-Other | 3.69% | — | +34.86% | |
| 11 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 3.37% | -0.59% | -12.59% | |
| 12 | NUVL | Nuvalent Inc-a | Stock-Other | 3.31% | -3.71% | EXIT | |
| 13 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 3.16% | — | +22.94% | |
| 14 | ✓ | Spdr Series Trust | Stock-Other | 3.06% | — | — | |
| 15 | ASND | Ascendis Pharma A/S | Stock-Other | 2.75% | -2.91% | EXIT | |
| 16 | CGON | Cg Oncology Inc | Stock-Other | 2.59% | -1.15% | EXIT | |
| 17 | VCYT | Veracyte Inc | Stock-Other | 2.24% | +1.35% | -29.24% | |
| 18 | SRRK | Scholar Rock Holding CORP | Stock-Other | 2.23% | -1.70% | EXIT | |
| 19 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 2.15% | — | -0.32% | |
| 20 | PCVX | Vaxcyte Inc | Stock-Other | 1.73% | +0.02% | — | |
| 21 | PFE | Pfizer Inc | Stock-Healthcare | 1.54% | — | — | |
| 22 | ✓ | Nuvalent Inc | Stock-Other | 1.41% | — | — | |
| 23 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 1.20% | — | — | |
| 24 | GOSS | Gossamer Bio Inc | Stock-Other | 1.17% | — | -18.57% | |
| 25 | ✓ | Stock-Other | 1.09% | — | +84.09% | ||
| 26 | ELUT | Elutia Inc | Stock-Other | 1.01% | -0.05% | +3.43% | |
| 27 | ✓ | Compugen LTD | Stock-Other | 1.00% | -0.01% | +4.78% | |
| 28 | TELA | Tela Bio Inc | Stock-Other | 0.99% | +0.03% | +0.31% | |
| 29 | ABEO | Abeona Therapeutics Inc | Stock-Other | 0.96% | +0.09% | — | |
| 30 | CDTX | Cidara Therapeutics Inc | Stock-Other | 0.93% | — | — | |
| 31 | CLDX | Celldex Therapeutics Inc | Stock-Other | 0.74% | -0.58% | EXIT | |
| 32 | AARD | Aardvark Therapeutics Inc | Stock-Other | 0.72% | -0.01% | EXIT | |
| 33 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 0.71% | — | — | |
| 34 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 0.70% | +0.64% | -69.22% | |
| 35 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.67% | — | -6.61% | |
| 36 | ✓ | Cogent Communications Hldgs | Stock-Other | 0.66% | — | — | |
| 37 | CERS | Cerus CORP | Stock-Other | 0.65% | +0.46% | +1.29% | |
| 38 | ERAS | Erasca Inc | Stock-Other | 0.60% | -0.66% | -65.13% | |
| 39 | CMPX | Compass Therapeutics Inc | Stock-Other | 0.60% | -0.46% | EXIT | |
| 40 | SION | Sionna Therapeutics Inc | Stock-Other | 0.60% | +0.03% | +62.97% | |
| 41 | BNTC | Benitec Biopharma Inc | Stock-Other | 0.55% | +0.17% | +1.29% | |
| 42 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.54% | +0.69% | +1.81% | |
| 43 | QURE | uniQure N.V. | Stock-Other | 0.52% | +0.50% | NEW | |
| 44 | ✓ | Hims & Hers Health Inc | Stock-Other | 0.46% | — | — | |
| 45 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 0.39% | — | -13.89% | |
| 46 | ORKA | Oruka Therapeutics Inc | Stock-Other | 0.34% | +2.73% | — | |
| 47 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 0.33% | -1.66% | -49.66% | |
| 48 | TRML | Tourmaline Bio Inc | Stock-Other | 0.32% | — | — | |
| 49 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 0.29% | — | -65.93% | |
| 50 | KOD | Kodiak Sciences Inc | Stock-Other | 0.28% | -1.65% | -9.11% |
According to official SEC Form 13F filings, Silverarc Capital Management, LLC reported a total U.S. public equity portfolio value of $962.2M across 65 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including MERUS N V, AKRO, VRNA) accounted for 17.0% of total reported equity market value during Q2 2025.
During Q2 2025, Silverarc Capital Management, LLC's top holdings by market value included MERUS N V (7.2%)、AKRO (7.0%)、VRNA (6.3%). The largest single position, MERUS N V, represented 7.2% of total portfolio value.
In Q2 2025, Silverarc Capital Management, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.